MacroGenics (MGNX) Stock Price
MacroGenics Price
Revenue has compounded at 8.6% per year over the past 14 years to 149.50 M USD. MacroGenics's net margin stands at -49.9%, up from -252.3% several years earlier. Analysts set a median price target of 3.06 USD, implying 17.1% below the current price. Of 13 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 177% above its 52-week low.
MacroGenics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of MacroGenics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MacroGenics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MacroGenics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | MacroGenics Price |
|---|---|
| 7/31/2026 | 3.69 USD |
| 7/30/2026 | 3.78 USD |
| 7/29/2026 | 3.68 USD |
| 7/27/2026 | 3.94 USD |
| 7/23/2026 | 4.01 USD |
| 7/22/2026 | 4.30 USD |
| 7/21/2026 | 4.54 USD |
| 7/20/2026 | 4.32 USD |
| 7/17/2026 | 4.49 USD |
| 7/16/2026 | 4.12 USD |
| 7/15/2026 | 4.32 USD |
| 7/14/2026 | 4.29 USD |
| 7/13/2026 | 4.47 USD |
| 7/10/2026 | 4.33 USD |
| 7/9/2026 | 4.57 USD |
| 7/8/2026 | 4.57 USD |
| 7/7/2026 | 4.75 USD |
| 7/6/2026 | 4.94 USD |
| 7/2/2026 | 4.71 USD |
| 7/1/2026 | 4.62 USD |
| 6/30/2026 | 4.62 USD |
| 6/29/2026 | 4.86 USD |
| 6/26/2026 | 4.81 USD |
| 6/25/2026 | 4.66 USD |
| 6/24/2026 | 4.78 USD |
| 6/23/2026 | 4.69 USD |
| 6/22/2026 | 4.18 USD |
| 6/18/2026 | 4.13 USD |
| 6/17/2026 | 3.96 USD |
| 6/16/2026 | 3.88 USD |
| 6/15/2026 | 4.13 USD |
| 6/12/2026 | 3.96 USD |
| 6/11/2026 | 4.01 USD |
| 6/10/2026 | 3.87 USD |
| 6/9/2026 | 3.91 USD |
| 6/8/2026 | 3.88 USD |
| 6/5/2026 | 3.91 USD |
| 6/4/2026 | 4.25 USD |
| 6/3/2026 | 4.20 USD |
| 6/2/2026 | 4.05 USD |
| 6/1/2026 | 4.14 USD |
| 5/29/2026 | 4.16 USD |
| 5/28/2026 | 4.21 USD |
| 5/27/2026 | 4.38 USD |
| 5/26/2026 | 4.47 USD |
| 5/22/2026 | 4.53 USD |
| 5/21/2026 | 4.24 USD |
| 5/20/2026 | 4.46 USD |
| 5/19/2026 | 4.52 USD |
| 5/18/2026 | 4.35 USD |
| 5/15/2026 | 4.25 USD |
| 5/14/2026 | 4.16 USD |
| 5/13/2026 | 3.45 USD |
| 5/12/2026 | 3.52 USD |
| 5/11/2026 | 2.95 USD |
| 5/8/2026 | 3.00 USD |
| 5/7/2026 | 2.94 USD |
| 5/6/2026 | 3.01 USD |
| 5/5/2026 | 3.15 USD |
| 5/4/2026 | 3.20 USD |
| 5/1/2026 | 3.13 USD |
| 4/30/2026 | 3.08 USD |
| 4/29/2026 | 2.94 USD |
| 4/28/2026 | 3.01 USD |
| 4/27/2026 | 3.05 USD |
| 4/24/2026 | 3.19 USD |
| 4/23/2026 | 3.32 USD |
| 4/22/2026 | 3.42 USD |
| 4/21/2026 | 3.47 USD |
| 4/20/2026 | 3.48 USD |
| 4/17/2026 | 3.46 USD |
| 4/16/2026 | 3.41 USD |
| 4/15/2026 | 3.52 USD |
| 4/14/2026 | 3.49 USD |
| 4/13/2026 | 3.47 USD |
| 4/10/2026 | 3.60 USD |
| 4/9/2026 | 3.44 USD |
| 4/8/2026 | 3.45 USD |
| 4/7/2026 | 3.35 USD |
| 4/6/2026 | 3.18 USD |
| 4/2/2026 | 3.07 USD |
| 4/1/2026 | 2.90 USD |
| 3/31/2026 | 2.89 USD |
| 3/30/2026 | 2.76 USD |
| 3/27/2026 | 2.93 USD |
| 3/26/2026 | 3.18 USD |
| 3/25/2026 | 3.17 USD |
| 3/24/2026 | 2.73 USD |
| 3/23/2026 | 2.92 USD |
| 3/20/2026 | 2.86 USD |
| 3/19/2026 | 2.90 USD |
| 3/18/2026 | 2.98 USD |
| 3/17/2026 | 3.08 USD |
| 3/16/2026 | 3.10 USD |
| 3/13/2026 | 3.00 USD |
| 3/12/2026 | 3.12 USD |
| 3/11/2026 | 3.34 USD |
| 3/10/2026 | 3.43 USD |
| 3/9/2026 | 2.36 USD |
| 3/6/2026 | 2.23 USD |
| 3/5/2026 | 2.14 USD |
| 3/4/2026 | 2.08 USD |
| 3/3/2026 | 1.90 USD |
| 3/2/2026 | 1.94 USD |
| 2/27/2026 | 1.99 USD |
| 2/26/2026 | 1.98 USD |
| 2/25/2026 | 1.92 USD |
| 2/24/2026 | 1.73 USD |
| 2/23/2026 | 1.75 USD |
| 2/20/2026 | 1.70 USD |
| 2/19/2026 | 1.73 USD |
| 2/18/2026 | 1.70 USD |
| 2/17/2026 | 1.70 USD |
| 2/13/2026 | 1.71 USD |
| 2/12/2026 | 1.71 USD |
| 2/11/2026 | 1.72 USD |
| 2/10/2026 | 1.71 USD |
| 2/9/2026 | 1.80 USD |
| 2/6/2026 | 1.81 USD |
| 2/5/2026 | 1.70 USD |
| 2/4/2026 | 1.73 USD |
| 2/3/2026 | 1.75 USD |
| 2/2/2026 | 1.75 USD |
| 1/30/2026 | 1.83 USD |
| 1/29/2026 | 1.93 USD |
| 1/28/2026 | 1.80 USD |
| 1/27/2026 | 1.84 USD |
| 1/26/2026 | 1.83 USD |
| 1/23/2026 | 1.80 USD |
| 1/22/2026 | 1.76 USD |
| 1/21/2026 | 1.74 USD |
| 1/20/2026 | 1.75 USD |
| 1/16/2026 | 1.72 USD |
| 1/15/2026 | 1.70 USD |
| 1/14/2026 | 1.78 USD |
| 1/13/2026 | 1.75 USD |
| 1/12/2026 | 1.79 USD |
| 1/9/2026 | 1.83 USD |
| 1/8/2026 | 1.79 USD |
| 1/7/2026 | 1.81 USD |
| 1/6/2026 | 1.70 USD |
| 1/5/2026 | 1.72 USD |
| 1/2/2026 | 1.61 USD |
| 12/31/2025 | 1.61 USD |
| 12/30/2025 | 1.56 USD |
| 12/29/2025 | 1.60 USD |
| 12/26/2025 | 1.61 USD |
| 12/24/2025 | 1.62 USD |
| 12/23/2025 | 1.60 USD |
| 12/22/2025 | 1.59 USD |
| 12/19/2025 | 1.50 USD |
| 12/18/2025 | 1.57 USD |
| 12/17/2025 | 1.61 USD |
| 12/16/2025 | 1.35 USD |
| 12/15/2025 | 1.37 USD |
| 12/12/2025 | 1.40 USD |
| 12/11/2025 | 1.41 USD |
| 12/10/2025 | 1.40 USD |
| 12/9/2025 | 1.39 USD |
| 12/8/2025 | 1.33 USD |
| 12/5/2025 | 1.37 USD |
| 12/4/2025 | 1.38 USD |
| 12/3/2025 | 1.40 USD |
| 12/2/2025 | 1.42 USD |
| 12/1/2025 | 1.46 USD |
| 11/28/2025 | 1.53 USD |
| 11/26/2025 | 1.48 USD |
| 11/25/2025 | 1.45 USD |
| 11/24/2025 | 1.42 USD |
| 11/21/2025 | 1.40 USD |
| 11/20/2025 | 1.37 USD |
| 11/19/2025 | 1.42 USD |
| 11/18/2025 | 1.54 USD |
| 11/17/2025 | 1.51 USD |
| 11/14/2025 | 1.50 USD |
| 11/13/2025 | 1.60 USD |
| 11/12/2025 | 1.47 USD |
| 11/11/2025 | 1.52 USD |
| 11/10/2025 | 1.43 USD |
| 11/7/2025 | 1.37 USD |
| 11/6/2025 | 1.36 USD |
| 11/5/2025 | 1.44 USD |
| 11/4/2025 | 1.45 USD |
| 11/3/2025 | 1.58 USD |
| 10/31/2025 | 1.66 USD |
| 10/30/2025 | 1.60 USD |
| 10/29/2025 | 1.69 USD |
| 10/28/2025 | 1.85 USD |
| 10/27/2025 | 1.91 USD |
| 10/24/2025 | 1.84 USD |
| 10/23/2025 | 1.83 USD |
| 10/22/2025 | 1.95 USD |
| 10/21/2025 | 2.02 USD |
| 10/20/2025 | 1.71 USD |
| 10/17/2025 | 1.65 USD |
| 10/16/2025 | 1.69 USD |
| 10/15/2025 | 1.69 USD |
| 10/14/2025 | 1.61 USD |
| 10/13/2025 | 1.64 USD |
| 10/10/2025 | 1.69 USD |
| 10/9/2025 | 1.75 USD |
| 10/8/2025 | 1.78 USD |
| 10/7/2025 | 1.72 USD |
| 10/6/2025 | 1.76 USD |
| 10/3/2025 | 1.78 USD |
| 10/2/2025 | 1.71 USD |
| 10/1/2025 | 1.70 USD |
| 9/30/2025 | 1.68 USD |
| 9/29/2025 | 1.75 USD |
| 9/26/2025 | 1.73 USD |
| 9/25/2025 | 1.65 USD |
| 9/24/2025 | 1.72 USD |
| 9/23/2025 | 1.66 USD |
| 9/22/2025 | 1.73 USD |
| 9/19/2025 | 1.62 USD |
| 9/18/2025 | 1.73 USD |
| 9/17/2025 | 1.53 USD |
| 9/16/2025 | 1.47 USD |
| 9/15/2025 | 1.56 USD |
| 9/12/2025 | 1.59 USD |
| 9/11/2025 | 1.65 USD |
| 9/10/2025 | 1.72 USD |
| 9/9/2025 | 1.73 USD |
| 9/8/2025 | 1.76 USD |
| 9/5/2025 | 2.00 USD |
| 9/4/2025 | 1.94 USD |
| 9/3/2025 | 1.91 USD |
| 9/2/2025 | 1.74 USD |
| 8/29/2025 | 1.77 USD |
| 8/28/2025 | 1.70 USD |
| 8/27/2025 | 1.72 USD |
| 8/26/2025 | 1.81 USD |
| 8/25/2025 | 1.64 USD |
| 8/22/2025 | 1.69 USD |
| 8/21/2025 | 1.44 USD |
| 8/20/2025 | 1.49 USD |
| 8/19/2025 | 1.49 USD |
| 8/18/2025 | 1.52 USD |
| 8/15/2025 | 1.58 USD |
| 8/14/2025 | 1.62 USD |
| 8/13/2025 | 1.66 USD |
| 8/12/2025 | 1.47 USD |
| 8/11/2025 | 1.47 USD |
| 8/8/2025 | 1.54 USD |
| 8/7/2025 | 1.61 USD |
| 8/6/2025 | 1.61 USD |
MacroGenics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
MacroGenics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.00 | 86.00 | 155.00 | 60.00 | 62.00 | 97.00 | 75.00 | 151.00 | 57.00 | 148.00 | 149.00 | 136.00 | 88.00 | 172.00 | 226.00 | 303.00 |
| 112.77 | -14.00 | 80.23 | -61.29 | 3.33 | 56.45 | -22.68 | 101.33 | -62.25 | 159.65 | 0.68 | -8.72 | -35.29 | 95.45 | 31.40 | 34.07 |
| 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 96.00 | 95.36 | 84.21 | 91.89 | 71.14 | 71.14 | 71.14 | 71.14 | 71.14 | 71.14 |
| 100.00 | 86.00 | 155.00 | 60.00 | 62.00 | 97.00 | 72.00 | 144.00 | 48.00 | 136.00 | 106.00 | 96.75 | 62.60 | 122.36 | 160.78 | 215.56 |
| -20.00 | -60.00 | -22.00 | -171.00 | -177.00 | -131.00 | -202.00 | -121.00 | -168.00 | -110.00 | -72.00 | -76.00 | -49.00 | -97.00 | -127.00 | -171.00 |
| -20.00 | -69.77 | -14.19 | -285.00 | -285.48 | -135.05 | -269.33 | -80.13 | -294.74 | -74.32 | -48.32 | -55.88 | -55.68 | -56.40 | -56.19 | -56.44 |
| -20.00 | -58.00 | -19.00 | -171.00 | -151.00 | -117.00 | -190.00 | -120.00 | -9.00 | -66.00 | -74.00 | -77.00 | -78.00 | -81.00 | -54.00 | -16.00 |
| -47.37 | 190.00 | -67.24 | 800.00 | -11.70 | -22.52 | 62.39 | -36.84 | -92.50 | 633.33 | 12.12 | 4.05 | 1.30 | 3.85 | -33.33 | -70.37 |
| 34.50 | 34.96 | 36.94 | 45.61 | 49.01 | 54.46 | 61.17 | 61.43 | 61.93 | 62.62 | 63.16 | 63.16 | 63.16 | 63.16 | 63.16 | 63.16 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales MacroGenics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MacroGenics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MacroGenics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares MacroGenics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MacroGenics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
MacroGenics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
MacroGenics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
MacroGenics business model & stock analysis
MacroGenics SWOT Analysis
Strengths
1. Strong research and development capabilities in the field of biotechnology.
2. Well-established strategic partnerships with leading pharmaceutical companies.
3. Robust intellectual property portfolio with numerous patents.
4. Skilled and experienced management team with expertise in the biotech industry.
Weaknesses
1. Heavy reliance on a limited number of drug candidates in the pipeline.
2. Vulnerability to regulatory challenges and delays in drug approvals.
3. High operating costs associated with the development and clinical trials of new drugs.
4. Limited market presence compared to larger pharmaceutical competitors.
Opportunities
1. Growing demand for novel biologic therapies in the healthcare market.
2. Potential expansion into international markets to increase revenue streams.
3. Collaborations with academic institutions for research advancements and talent acquisition.
4. Increasing investments in precision medicine and personalized healthcare.
Threats
1. Intense competition from other biotech and pharmaceutical companies.
2. Rising costs of research and development, potentially impacting profitability.
3. Regulatory changes and stricter compliance requirements for drug development and commercialization.
4. Uncertainties associated with the outcome of clinical trials and drug efficacy.
MacroGenics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
MacroGenics Segments
MacroGenics Revenue by Segment
3 Years
5 Years
Max
Details
MacroGenics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
MacroGenics historical P/E ratio, EBIT multiple, and P/S ratio
MacroGenics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
MacroGenics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current MacroGenics forecasts and price targets in August 2026
Analyst Price Targets 2026MacroGenics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 4/20/2026 | Maintained | Overweight | 33 | |
| 4/10/2026 | Upgrade | NeutralBuy | – | |
| 3/10/2026 | Maintained | Overweight | 33 | |
| 11/3/2025 | Maintained | Neutral | – | |
| 8/15/2025 | Maintained | Outperform | – | |
| 5/20/2025 | Maintained | Neutral | – | |
| 5/14/2025 | Maintained | Hold | – | |
| 5/14/2025 | Maintained | Overweight | 33 | |
| 3/25/2025 | Maintained | Neutral | – | |
| 11/7/2024 | Downgrade | Market OutperformMarket Perform | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
MacroGenics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.13USD | - | 68.80 MUSD | - | 2026 Q2 |
| 5/13/2026 | -0.58USD | - | 15.35 MUSD | - | 2026 Q1 |
| 3/18/2026 | -0.30USD | - | 23.10 MUSD | - | 2025 Q4 |
| 5/7/2024 | -0.48USD | - | 15.62 MUSD | - | 2024 Q1 |
| 3/13/2024 | -0.13USD | - | 34.84 MUSD | - | 2023 Q4 |
| 8/7/2023 | -0.50USD | - | 24.61 MUSD | - | 2023 Q2 |
| 5/1/2023 | -0.42USD | - | 30.53 MUSD | - | 2023 Q1 |
| 2/22/2023 | 0.16USD | - | 74.24 MUSD | - | 2022 Q4 |
| 11/3/2022 | -0.39USD | - | 34.34 MUSD | - | 2022 Q3 |
| 8/8/2022 | -0.99USD | - | 13.98 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the MacroGenics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
MacroGenics shareholder structure
| % | Name |
|---|---|
15.68130% | |
9.42144% | |
6.66000% | |
5.13914% | |
5.02002% | |
3.93883% |
MacroGenics Beneficial Ownership Filings (SEC 13D/G)
MacroGenics Executives and Management Board
16 members · avg. age 63 · 31 % women
Dr. Stephen Eck (70)
Senior Vice President - Clinical Development, Chief Medical Officer
2.65 M USD
Management
Mr. James Karrels (58)
Chief Financial Officer, Senior Vice President, Corporate Secretary
Dr. Ezio Bonvini (71)
Senior Vice President - Research, Chief Scientific Officer
Mr. Eric Risser (52)
President, Chief Executive Officer, Director · since 2009
Mr. Thomas Spitznagel (58)
Senior Vice President - Technical Operations
Mr. Jeffrey Peters (54)
Senior Vice President, General Counsel, Corporate Compliance Officer
Ms. Beth Smith (57)
Vice President, Controller, Treasurer
Board of Directors
Mr. William Heiden (65)
Independent Chairman of the Board
Ms. Federica O'Brien (67)
Independent Director
Dr. David Stump (75)
Independent Director
Mr. Scott Jackson (59)
Independent Director
Ms. Meenu Chhabra Karson (52)
Independent Director
Dr. Karen Ferrante (67)
Independent Director
MacroGenics Supply Chain
MacroGenics Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.76 | 0.80 | 0.72 | ||
| 2 | I-MAB ADR | 0.94 | 0.97 | 0.57 | |
| 3 | -0.39 | 0.06 | 0.49 | ||
| 4 | 0.19 | 0.45 | 0.45 | ||
| 5 | 0.72 | 0.12 | 0.35 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.88 | 0.93 | — | ||
| 2 | 0.47 | -0.50 | -0.71 | ||
| 3 | -0.73 | -0.43 | -0.50 | ||
| 4 | 0.77 | 0.14 | -0.39 | ||
| 5 | 0.58 | 0.58 | -0.27 |
Frequently asked questions about MacroGenics
The business model of MacroGenics Inc is focused on developing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary technology platforms to discover, design, and optimize monoclonal and multi-specific antibodies. By leveraging its expertise in antibody engineering and targeting mechanisms, MacroGenics aims to create novel therapies that have the potential to improve patient outcomes. With a strong pipeline of product candidates targeting various cancer indications, MacroGenics Inc strives to advance medical innovation and bring transformative treatments to patients in need.
MacroGenics Inc is primarily active in the biotechnology industry.
The main competitors of MacroGenics Inc in the market include larger pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, and Novartis. These companies also operate in the biopharmaceutical industry and have a similar focus on developing innovative therapies and treatments. MacroGenics Inc faces competition from these established players in terms of product development, market share, and financial performance. However, MacroGenics Inc has its own unique portfolio of proprietary drug candidates and strategic collaborations which help it remain competitive in the market.
MacroGenics Inc is a biopharmaceutical company based in Rockville, Maryland. Established in 2000, MacroGenics has been dedicated to developing innovative antibody-based therapies for patients with cancer and autoimmune disorders. With a strong focus on research and development, the company has built a robust pipeline of product candidates targeting different diseases. MacroGenics has achieved several milestones, including FDA approvals and collaborations with notable pharmaceutical companies. With its experienced team and cutting-edge technology, MacroGenics continues to strive towards improving patients' lives through the development of novel therapies.
MacroGenics Inc, a renowned biopharmaceutical company, has achieved several significant milestones in its impressive journey. Notably, the company successfully developed and received regulatory approvals for multiple clinical-stage product candidates, showcasing its commitment to advancing innovative therapies. MacroGenics Inc's most notable achievement includes the FDA approval of margetuximab, a treatment for patients with HER2-positive metastatic breast cancer. Moreover, the company has established strategic collaborations with leading pharmaceutical companies, further validating its research and development capabilities. With its strong focus on precision medicine and novel antibody-based therapeutics, MacroGenics Inc continues to drive breakthrough advancements in the field of biotechnology.
MacroGenics Inc is primarily present in the United States.
The values and corporate philosophy that MacroGenics Inc represents are centered around their commitment to discovering and developing innovative biopharmaceutical products. The company strives to deliver impactful medicines to improve the lives of patients. MacroGenics Inc focuses on excellence, integrity, and collaboration in their research and development efforts. They aim to be a trusted partner and create value for their stakeholders through their cutting-edge science and dedication to advancing healthcare. With a focus on science-driven discovery and a patient-centric approach, MacroGenics Inc aims to bring transformative therapies to market.
Analysts currently set an average price target of 3.47 USD for the MacroGenics stock (median: 3.06 USD), implying -11.2 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the MacroGenics stock: 7 recommend buying, 6 holding and 0 selling. For 2026, analysts expect MacroGenics to generate revenue of 136.26 M USD and earnings per share of -1.23 USD.
Converted at the current exchange rate, the MacroGenics share trades at 3.20 EUR (3.69 USD).
The MacroGenics share (MGNX) is listed on 4 stock exchanges, including: NASDAQ (MGNX), Frankfurt (M55.F), Düsseldorf (M55.DU), SIX (Zürich) (M55.SW).
MacroGenics Inc is a biopharmaceutical company that focuses on developing immunotherapy products for cancer and autoimmune diseases. The company aims to develop innovative therapies that can improve the lives of patients. The business model of MacroGenics comprises three main divisions: research, development, and commercialization. The company investigates the mechanisms behind the immune system to develop targeted products that can enhance immune control in diseases. To do this, the company utilizes its proprietary technology platform, the Dual-Affinity Re-Targeting (DART) technology. MacroGenics' research division focuses on the development of novel immunotherapies. An important focus is on the development of bispecific antibodies (BiTEs), which can specifically recognize and target two different antigens on tumor cells. The company already has several such products in the development phase, including MGD015, MGD017, and MGD019. MacroGenics' development division is involved in the manufacturing and testing of therapeutics and drugs that have emerged from the research division. The company has several products on the market, including the cancer immunotherapy Margetuximab (Margenza®) and Aes-103, a nasal spray for pain in cancer patients. The commercialization division of MacroGenics is responsible for the global marketing of the company's products. It also works closely with licensees and partners. One important partner of MacroGenics is Incyte Corporation, with whom the company collaborates on the development of cancer immunotherapies. MacroGenics also pursues a diversification strategy and expands into new therapy areas. The company recently entered into a partnership with Zai Lab Ltd. to jointly develop a novel antibody-drug conjugate (ADC) against HER2-positive cancer. The company has also initiated a program for the development of drugs for autoimmune diseases, including therapeutic antibodies. In addition to its commercial products, MacroGenics is also a leading provider of research services in the field of antibody and protein engineering and manufacturing. The company offers customized solutions for customers in the academic, pharmaceutical, and biotechnology sectors. Overall, MacroGenics' business model is aimed at advancing the development of innovative immunotherapy products and marketing them worldwide. With a broad product portfolio and an extensive research and development pipeline, the company is in a strong position to ensure the growth and success of the company in the future.
The expected revenue of MacroGenics is 136.26 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of MacroGenics is -77.75 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of MacroGenics is currently -3.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MacroGenics stock.
The price-to-sales ratio (P/S) of MacroGenics is currently 1.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MacroGenics stock.
The Eulerpool Quality Score for MacroGenics is 2/10.
The ISIN of MacroGenics is US5560991094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of MacroGenics is A1W6ND. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of MacroGenics is MGNX. The ticker symbol is used to trade MacroGenics shares on the stock exchange.
MacroGenics paid dividends every year for the past 0 years.
MacroGenics is assigned to the 'Health' sector.
The dividends of MacroGenics are distributed in USD.
MacroGenics stock
MacroGenics Peer Group
MacroGenics Ticker
MacroGenics FIGI
All fundamentals and in-depth analysis of MacroGenics
Our stock analysis for MacroGenics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MacroGenics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.